CG Oncology, Inc.
CGON- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001991792
In the last 90 days, CG Oncology, Inc. insiders filed 0 open-market purchases and 3 sales; 229 institutions reported holding it in 13F filings for Q2 2026, worth $6.66B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $6.68B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $209.6K in total
- 3
- 13F holdersQ2 2026, −4 vs. previous quarter
- 229
- 13F valueReported value at the end of Q2 2026
- $6.66B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $4.04M
- +254.7% year over year
- Net income, FY2025
- -$161.0M
- No comparable prior period
- Free cash flow, FY2025
- -$132.5M
- No comparable prior period
- Revenue, Q3 FY2026
- $1.60M
- −3.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $161.0M (3985.0% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 8.87M
- Shares sold short
- Change
- −1.57M
- −15.0% vs. previous
- Days to cover
- 9.65
- At average daily volume
Superinvestors holding CGON, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CGON at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by CG Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 (view filing)4:30 PM ET | Oct 15 | 4 days | Post Leonard EDirector | SSale | −1.00K | $62.07 | −$62.1K | −100.0%0 after | 2 lots10b5-1 |
| Sep 17, 2026 (view filing)4:30 PM ET | Sep 15 | 2 days | Post Leonard EDirector | SSale | −1.00K | $72.98 | −$73.0K | −100.0%0 after | 10b5-1 |
| Aug 18, 2026 (view filing)4:30 PM ET | Aug 14 | 4 days | Post Leonard EDirector | SSale | −1.00K | $74.54 | −$74.5K | −100.0%0 after | 10b5-1 |
| Jul 17, 2026 (view filing)4:15 PM ET | Jul 15 | 2 days | Post Leonard EDirector | SSale | −1.00K | $71.17 | −$71.2K | −100.0%0 after | 10b5-1 |
| Jul 14, 2026 (view filing)4:15 PM ET | Jul 10 | 4 days | Mulay JamesDirector | SSale | −24.2K | $75.16 | −$1.82M | −100.0%0 after | 10b5-1 |
| Jun 29, 2026 (view filing) | Jun 25 | 4 days | Liu Brian Guan-ChyunDirector | PPurchase | +371.1K | $66.87 | +$24.8M | +24.5%1.89M after | 10b5-1 |
| Jun 25, 2026 (view filing) | Jun 24 | 1 day | Post Leonard EDirector | SSale | −5.00K | $70.00 | −$350.0K | −100.0%0 after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Post Leonard EDirector | SSale | −5.00K | $65.00 | −$325.0K | −100.0%0 after | 10b5-1 |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Mulay JamesDirector | SSale | −1.96K | $60.12 | −$118.1K | −100.0%0 after | 2 lots10b5-1 |
| Jun 5, 2026 (view filing) | Jun 4 | 1 day | Post Leonard EDirector | SSale | −1.00K | $54.50 | −$54.5K | −100.0%0 after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 229 holdersThe largest institutional positions in CG Oncology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RTW Investments, LP | 8,514,590 | $605.0M | 5.16% | +1,529,782+21.9% | Added |
| T. Rowe Price Investment Management, Inc. | 6,616,899 | $470.1M | 0.31% | −103,490−1.5% | Reduced |
| Decheng Capital LLC | 6,371,669 | $452.7M | 61.87% | 00.0% | Unchanged |
| BlackRock, Inc. | 6,256,288 | $444.5M | 0.01% | +1,192,108+23.5% | Added |
| Wellington Management Group LLP | 5,324,751 | $378.3M | 0.07% | −46,481−0.9% | Reduced |
| FMR LLC | 4,161,493 | $295.7M | 0.01% | +396,649+10.5% | Added |
| Price T Rowe Associates Inc | 3,805,010 | $270.3M | 0.03% | +152,030+4.2% | Added |
| TCG Crossover Management, LLC | 3,670,206 | $260.8M | 6.27% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 3,465,197 | $246.2M | 0.01% | +370,099+12.0% | Added |
| State Street Corp | 3,437,590 | $244.2M | 0.01% | +790,536+29.9% | Added |
Holders of 5% or more of CGON
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of CG Oncology, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| RTW Investments, LP | 13G/A | 9.70%8.51M shares | +1.40 ppfrom 8.30% | May 15, 20262 filings | Aug 14, 2026 | SEC |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 13G/A | 8.40%6.37M shares | – | Feb 8, 20243 filings | Feb 14, 2025 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G | 8.00%6.72M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.80%6.02M shares | – | Oct 22, 20243 filings | Jul 27, 2026 | SEC |
| Wellington Management Group LLP | 13G/A | 6.00%5.32M shares | −1.20 ppfrom 7.20% | Nov 12, 20252 filings | Aug 13, 2026 | SEC |